MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 585174 | Name: SM 12502

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SM 12502 is a substrate for cytochrome P450 2A6 in human liver microsomes.

Chemical Structure

SM 12502
SM 12502
CAS#158511-47-8

Theoretical Analysis

MedKoo Cat#: 585174

Name: SM 12502

CAS#: 158511-47-8

Chemical Formula: C10H13ClN2OS

Exact Mass: 244.0437

Molecular Weight: 244.74

Elemental Analysis: C, 49.08; H, 5.35; Cl, 14.48; N, 11.45; O, 6.54; S, 13.10

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
SM 12502; SM12502; SM-12502
IUPAC/Chemical Name
( )-cis-3,5-Dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride
InChi Key
CXHDSLQCNYLQND-XQRIHRDZSA-N
InChi Code
InChI=1S/C10H12N2OS.ClH/c1-7-9(13)12(2)10(14-7)8-4-3-5-11-6-8;/h3-7,10H,1-2H3;1H/t7-,10+;/m0./s1
SMILES Code
O=C1N(C)[C@@H](C2=CC=CN=C2)S[C@H]1C.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 244.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Tanner JA, Tyndale RF. Variation in CYP2A6 Activity and Personalized Medicine. J Pers Med. 2017 Dec 1;7(4). pii: E18. doi: 10.3390/jpm7040018. Review. PubMed PMID: 29194389; PubMed Central PMCID: PMC5748630. 2: Hayashi J, Hiromura K, Koizumi R, Shimizu Y, Maezawa A, Nojima Y, Naruse T. Platelet-activating factor antagonist, SM-12502, attenuates experimental glomerular thrombosis in rats. Nephron. 2001 Mar;87(3):274-8. PubMed PMID: 11287764. 3: Nunoya K, Yokoi Y, Kimura K, Kodama T, Funayama M, Inoue K, Nagashima K, Funae Y, Shimada N, Green C, Kamataki T. (+)-cis-3,5-dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride (SM-12502) as a novel substrate for cytochrome P450 2A6 in human liver microsomes. J Pharmacol Exp Ther. 1996 May;277(2):768-74. PubMed PMID: 8627557. 4: Nunoya K, Yokoi T, Kimura K, Inoue K, Kodama T, Funayama M, Nagashima K, Funae Y, Green C, Kinoshita M, Kamataki T. A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502). Pharmacogenetics. 1998 Jun;8(3):239-49. PubMed PMID: 9682269. 5: Murakami K, Okajima K, Uchiba M, Johno M, Okabe H, Takatsuki K. A novel platelet activating factor antagonist, SM-12502, attenuates endotoxin-induced disseminated intravascular coagulation and acute pulmonary vascular injury by inhibiting TNF production in rats. Thromb Haemost. 1996 Jun;75(6):965-70. PubMed PMID: 8822594. 6: Köller M, Hilger RA, König W. Effect of the PAF-receptor antagonist SM-12502 on human platelets. Inflammation. 1996 Feb;20(1):71-85. PubMed PMID: 8926050. 7: Hilger RA, Köller M, König W. Inhibition of leukotriene formation and IL-8 release by the paf-receptor antagonist SM-12502. Inflammation. 1996 Feb;20(1):57-70. PubMed PMID: 8926049. 8: Morooka S, Natsume Y. Effect of SM-12502 on disseminated intravascular coagulation (DIC) in tumor-bearing rats. Adv Exp Med Biol. 1996;416:189-93. PubMed PMID: 9131147. 9: Nunoya KI, Yokoi T, Kimura K, Kainuma T, Satoh K, Kinoshita M, Kamataki T. A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans. J Pharmacol Exp Ther. 1999 Apr;289(1):437-42. PubMed PMID: 10087035. 10: Imanishi N, Murakami-Uchida M, Koike H, Natsume Y, Morooka S. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride. Arzneimittelforschung. 1994 Mar;44(3):317-22. PubMed PMID: 8192697. 11: Todoroki H, Higure A, Okamoto K, Okazaki K, Nagafuchi Y, Takeda S, Katoh H, Itoh H, Ohsato K, Nakamura S. Possible role of platelet-activating factor in the in vivo expression of tissue factor in neutrophils. J Surg Res. 1998 Dec;80(2):149-55. PubMed PMID: 9878306. 12: Kamataki T. [How I was enticed into molecular toxicology]. Yakugaku Zasshi. 2006 Dec;126(12):1309-18. Review. Japanese. PubMed PMID: 17139156. 13: Damas J, Remacle-Volon G, Bourdon V. Platelet-activating factor and the vascular effects of zymosan in rats. Eur J Pharmacol. 1993 Feb 9;231(2):231-6. PubMed PMID: 8453979. 14: Nunoya K, Yokoi T, Itoh K, Itoh S, Kimura K, Kamataki T. S-oxidation of (+)-cis-3,5-dimethyl-2-(3-pyridyl)-thiazolidin-4-one hydrochloride by rat hepatic flavin-containing monooxygenase 1 expressed in yeast. Xenobiotica. 1995 Dec;25(12):1283-91. PubMed PMID: 8719904. 15: Kamataki T, Fujieda M, Kiyotani K, Iwano S, Kunitoh H. Genetic polymorphism of CYP2A6 as one of the potential determinants of tobacco-related cancer risk. Biochem Biophys Res Commun. 2005 Dec 9;338(1):306-10. Epub 2005 Sep 15. Review. PubMed PMID: 16176798. 16: Suzuki M, Sugatani J, Ino M, Shimura M, Akiyama M, Yamazaki R, Suzuki Y, Miwa M. Continuous binding of the PAF molecule to its receptor is necessary for the long-term aggregation of platelets. Am J Physiol. 1998 Jan;274(1):C47-57. doi: 10.1152/ajpcell.1998.274.1.C47. PubMed PMID: 9458712. 17: Uchida M, Imanishi N, Sugasawa T, Morooka S. Effect of the selective PAF antagonist SM-10661 on an asthmatic model. 1. Effect on passive anaphylactic bronchoconstriction in guinea pigs. Lipids. 1991 Dec;26(12):1301-4. PubMed PMID: 1819720. 18: Yokoi T, Kamataki T. [Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese]. Nihon Yakurigaku Zasshi. 1998 Jul;112(1):5-14. Review. Japanese. PubMed PMID: 9755457. 19: Komuro Y, Imanishi N, Uchida M, Morooka S. Biological effect of orally active platelet-activating factor receptor antagonist SM-10661. Mol Pharmacol. 1990 Sep;38(3):378-84. PubMed PMID: 2402227. 20: Mushiroda T, Ariyoshi N, Kimura K, Takahara E, Nagata O, Kato H, Kamataki T. A high-level expression of CYP2A in the lung of the suncus (Suncus murinus) and its role in the activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Biochem Biophys Res Commun. 2000 Mar 16;269(2):393-6. PubMed PMID: 10708563.